title: Linezolid and clindamycin improve the outcome of severe, necrotizing pneumonia due to community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA).
abstract: The last decade has been characterized by the emergence of CA-MRSA strains associated with the production of Panton-Valentine leukocidin. We report a case of necrotizing pneumonia and septic shock caused by CA-MRSA, in which early recognition of the syndrome and appropriate treatment with two toxin-suppressing antibiotics improved the patient's outcome.
authors.affiliation: USC Malattie Infettive, Ospedali Riuniti di Bergamo, Italy.
authors.forename: Laura
authors.initials: L
authors.lastname: Soavi
authors.forename: Liana
authors.initials: L
authors.lastname: Signorini
authors.forename: Roberto
authors.initials: R
authors.lastname: Stellini
authors.forename: Annamaria
authors.initials: A
authors.lastname: Acquarolo
authors.forename: Bertilla
authors.initials: B
authors.lastname: Fiorese
authors.forename: Silvia
authors.initials: S
authors.lastname: Magri
authors.forename: Annalisa
authors.initials: A
authors.lastname: Pantosti
authors.forename: Fredy
authors.initials: F
authors.lastname: Suter
authors.forename: Giampiero
authors.initials: G
authors.lastname: Carori
mesh_terms: D000081:Acetamides / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D000935:Antifungal Agents / Q000627:therapeutic use; D000077336:Caspofungin; D002981:Clindamycin / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D017714:Community-Acquired Infections / Q000188:drug therapy* / Q000382:microbiology; D004359:Drug Therapy, Combination; D054714:Echinocandins / Q000627:therapeutic use; D005260:Female; D006440:Hemofiltration; D006801:Humans; D006854:Hydrocortisone / Q000627:therapeutic use; D000069349:Linezolid; D055666:Lipopeptides; D055624:Methicillin-Resistant Staphylococcus aureus / Q000187:drug effects / Q000302:isolation & purification*; D008875:Middle Aged; D009336:Necrosis; D023303:Oxazolidinones / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D010102:Oxygen Inhalation Therapy; D018410:Pneumonia, Bacterial / Q000188:drug therapy* / Q000382:microbiology / Q000628:therapy; D055732:Pulmonary Aspergillosis / Q000150:complications / Q000188:drug therapy; D012121:Respiration, Artificial; D012772:Shock, Septic / Q000188:drug therapy / Q000209:etiology / Q000628:therapy; D013203:Staphylococcal Infections / Q000188:drug therapy* / Q000382:microbiology
chemical_list: D000081:Acetamides; D000900:Anti-Bacterial Agents; D000935:Antifungal Agents; D054714:Echinocandins; D055666:Lipopeptides; D023303:Oxazolidinones; D002981:Clindamycin; D000077336:Caspofungin; D000069349:Linezolid; D006854:Hydrocortisone